Cargando…

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

BACKGROUND: Pemetrexed is used for the treatment for non-small cell lung cancer and mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is unknown what dose is well tolerated in this population. OBJECTIVE: The purpose of our study was to investigate the pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Rouw, Nikki, Boosman, Rene J., Huitema, Alwin D. R., Hilbrands, Luuk B., Svensson, Elin M., Derijks, Hieronymus J., van den Heuvel, Michel M., Burger, David M., ter Heine, Rob
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113206/ https://www.ncbi.nlm.nih.gov/pubmed/33420970 http://dx.doi.org/10.1007/s40262-020-00972-1

Ejemplares similares

The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer
por: de Rouw, Nikki, et al.
Publicado: (2022)

Hyperhydration with cisplatin does not influence pemetrexed exposure
por: de Rouw, Nikki, et al.
Publicado: (2021)

A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions
por: de Rouw, Nikki, et al.
Publicado: (2019)

Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial
por: de Rouw, Nikki, et al.
Publicado: (2022)

Highly sensitive quantification of pemetrexed in human plasma using UPLC‐MS/MS to support microdosing studies
por: van Ewijk‐Beneken Kolmer, Eleonora W. J., et al.
Publicado: (2021)

A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients
por: van Erp, Nielka P., et al.
Publicado: (2016)

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
por: Wasmann, Roeland E., et al.
Publicado: (2020)

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
por: Schalkwijk, Stein, et al.
Publicado: (2018)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
por: Koele, Simon E., et al.
Publicado: (2021)

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules
por: Li, K M, et al.
Publicado: (2007)

Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients
por: ter Heine, Rob, et al.
Publicado: (2020)

Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient
por: Bouwmeester, Romy N., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps
por: van der Galiën, Ruben, et al.
Publicado: (2018)

A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
por: ter Heine, Rob, et al.
Publicado: (2023)

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
por: Wijnsma, Kioa Lente, et al.
Publicado: (2019)

Correction to: An Integral Pharmacokinetic Analysis of Piperacillin and Tazobactam in Plasma and Urine in Critically Ill Patients
por: Wallenburg, Eveline, et al.
Publicado: (2022)

Correction to: A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
por: van Beek, Stijn W., et al.
Publicado: (2021)

High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints
por: Jansen, Anouk M. E., et al.
Publicado: (2023)

Repurposing antifungals: population pharmacokinetics of itraconazole and hydroxy-itraconazole following administration of a nanocrystal formulation
por: Jansen, Anouk M E, et al.
Publicado: (2023)

Pharmacokinetic boosting to enable a once-daily reduced dose of tofacitinib in patients with rheumatoid arthritis and psoriatic arthritis (the PRACTICAL study)
por: van der Togt, Céleste J.T., et al.
Publicado: (2022)

A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV
por: Bukkems, Vera E., et al.
Publicado: (2021)

Practical recommendations to combine small-molecule inhibitors and direct oral anticoagulants in patients with nonsmall cell lung cancer
por: Otten, Leila S., et al.
Publicado: (2022)

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer
por: Crombag, Marie-Rose B.S., et al.
Publicado: (2016)

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
por: Keizer, Ron J, et al.
Publicado: (2015)

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
por: Jacobs, Tom G, et al.
Publicado: (2020)

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
por: Litjens, Carlijn H. C., et al.
Publicado: (2023)

Clinical Pharmacokinetics and Impact of Hematocrit on Monitoring and Dosing of Tacrolimus Early After Heart and Lung Transplantation
por: Sikma, Maaike A., et al.
Publicado: (2019)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
por: Litjens, Carlijn H. C., et al.
Publicado: (2021)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs
por: Schooley, Robert T., et al.
Publicado: (2021)

Immunosuppressive Drugs and COVID-19: A Review
por: Schoot, Tessa S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hapfihe8dokne4mqk0jepbrj7u